CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 59 filers reported holding CATABASIS PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $3,412,000 | – | 1,617,000 | – | 1.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soleus Capital Management, L.P. | 775,000 | $2,240,000 | 0.40% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,294,000 | $3,740,000 | 0.29% |
| ArchPoint Investors | 162,826 | $471,000 | 0.13% |
| Ikarian Capital, LLC | 852,998 | $2,464,000 | 0.08% |
| Samsara BioCapital, LLC | 150,000 | $434,000 | 0.08% |
| Perceptive Advisors | 1,933,551 | $5,588,000 | 0.07% |
| Fairmount Funds Management LLC | 53,166 | $154,000 | 0.06% |
| Alyeska Investment Group, L.P. | 1,124,623 | $3,250,000 | 0.04% |
| Alyeska Investment Group, L.P. | 731,303 | $2,113,000 | 0.03% |
| Corient Capital Partners, LLC | 103,523 | $299,000 | 0.03% |